# Pazopanib in Relapsed and Refractory Small Cell Lung Cancer

> **NCT01713296** · PHASE2 · COMPLETED · sponsor: **Hellenic Oncology Research Group** · enrollment: 58 (actual)

## Conditions studied

- SCLC

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01713296
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2015-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01713296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01713296, "Pazopanib in Relapsed and Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01713296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*